Darnitsa to Manufacture Additional Batches of Imustat

In April Darnitsa Pharmaceutical Company will manufacture additional batches of Imustat, antiviral drug.

Under the circumstances of the COVID-19 pandemic and imposed quarantine, an additional demand for antiviral drugs appeared in Ukraine. In light of this, every day the Company receives hundreds of requests from throughout Ukraine of the desire to purchase Imustat.

Darnitsa has set itself a priority to provide the Ukrainians with the medicines they need in the current situation and to do this at maximum speed. That is why we have created the proper conditions to start additional production of 100,000 packs of Imustat, antiviral drug, on March 26.

“We understand that the situation today requires a lightning-quick reaction. Therefore, we have modified our production plans and prioritized the release of the drugs used to prevent and treat symptoms of viral infections. Imustat is recommended for adults to reduce the duration and severity of the disease and to alleviate its main symptoms. We have made every effort to start manufacturing additional 100,000 packs of this drug on March 26,” reported Dmytro Shymkiv, Chairman of the Board of Directors of Darnitsa Group.

Darnitsa will give further notice of the delivery of Imustat to pharmacies in Ukraine.

Imustat is an antiviral medicine, which is available in tablets. It is recommended for adults to reduce the duration and severity of the disease and to alleviate its main symptoms. The use of the drug reduces the incidence of complications associated with the flu. Imustat is low-toxic and does not have a negative impact on the human body.